---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-050242"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:14:56.769437+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma corporate deck touts bird flu TXM data, COVID plans, $15.9M cash

## Summary
- TXM bird flu: 100% survival in mice, dose-dependent survival in ferrets; single dose maintained plasma >EC90 for ~3 weeks in Phase 1.
- Pursuing FDA Animal Rule for bird flu; FDA meeting granted, briefing package submitted April 24, 2025.
- COVID candidate ratutrelvir: ritonavir-independent 10-day regimen; briefing document planned for June 2025.
- Cash $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.
- Legacy oncology assets (rigosertib, narazaciclib) remain; pursuing business development exit strategies.

## SEC filing metadata
- accession: 0001104659-25-050242
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925050242/0001104659-25-050242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925050242/tm2515458d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-050242
- JSON: https://secwatch.observer/filing/0001104659-25-050242.json
- Plain text: https://secwatch.observer/filing/0001104659-25-050242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.